Why the study?
Is plasma bio-ADM associated with clinical signs of congestion in patients with new-onset and worsening heart failure?
Is plasma bio-ADM associated with clinical signs of congestion in patients with new-onset and worsening heart failure?
Bio-ADM is a potential biomarker of congestion that may be useful to guide decongestive therapy in heart failure patients.
Bio-ADM may reflect congestion severity in HF; hypothesis-generating and requires prospective validation before guiding therapy.
Plasma bio-ADM in patients with new-onset and worsening HF is associated with more severe HF and more oedema, orthopnoea, hepatomegaly and jugular venous pressure. We therefore postulate bio-ADM as a congestion marker, which might become useful to guide decongestive therapy.
No takes yet. Share an insight, caveat, or question.
Maaten et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: